Alter

Redefining precision oncology,
one
alteration at a time

We are a clinical-stage precision oncology company built on rigorous science and relentless execution. In four years, we’ve taken two internally discovered first-of-their-kind alteration-specific cancer therapies from idea to clinic, driven by a team that blends deep biology and chemistry expertise with advanced computational and physics-based drug design.

We’re tackling two of cancer’s most challenging targets: Mutant KRAS and mutant AKT E17K. These are high-impact drivers of cancer that have eluded conventional drug development for decades, especially in cancers such as non-small cell lung, pancreatic, colorectal, endometrial, and breast.